Cardiorenal and Endocrine Effects of Synthetic Canine BNP1-32 in Dogs with Compensated Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2019 Feb 1

PMID 30703246

Citations 2

Authors

Mariko Yata

Hans S Kooistra

Niek J Beijerink

Affiliations

Soon will be listed here.

Abstract

Background: The effects of synthetic brain natriuretic peptide (BNP1-32) on cardiorenal and renin angiotensin aldosterone system in dogs with naturally occurring congestive heart failure (CHF) are unknown.

Objectives: To evaluate the cardiorenal and endocrine effects of SC administered synthetic canine BNP1-32, with or without furosemide, in dogs with CHF caused by myxomatous mitral valve disease (MMVD).

Animals: Seven client-owned male dogs with compensated American College of Veterinary Internal Medicine stage C CHF caused by MMVD on chronic treatment with furosemide, benazepril, and pimobendan.

Methods: A single-dose, crossover, pilot study. Each dog received a dose of BNP1-32 (5 μg/kg), furosemide (2 mg/kg), and both BNP1-32/furosemide (5 μg/kg and 2 mg/kg, respectively) SC with a 2-week washout period among each treatment. Between- and within-treatment effects were evaluated using linear mixed modeling with restricted maximum likelihood estimation and evaluation of least square differences.

Results: Rapid absorption of BNP1-32 and a corresponding rise in urinary cyclic guanosine monophosphate excretion was observed at 1-2 hours after any treatment containing BNP1-32 (P < .05). However, BNP1-32 did not influence measured cardiorenal variables. Plasma aldosterone concentrations were below quantifiable levels in majority of the samples.

Conclusions And Clinical Importance: No beneficial cardiorenal effects were detected. It is possible that dogs with chronic CHF have a reduction in natriuretic peptide responsiveness.

Citing Articles

Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Bagardi M, Zamboni V, Locatelli C, Galizzi A, Ghilardi S, Brambilla P Animals (Basel). 2022; 12(2).

PMID: 35049831 PMC: 8773235. DOI: 10.3390/ani12020209.

Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.

Yata M, Kooistra H, Beijerink N J Vet Intern Med. 2019; 33(2):462-470.

PMID: 30703246 PMC: 6430907. DOI: 10.1111/jvim.15416.

References

Borgarelli M, Buchanan J . Historical review, epidemiology and natural history of degenerative mitral valve disease. J Vet Cardiol. 2012; 14(1):93-101. DOI: 10.1016/j.jvc.2012.01.011. View

Bernay F, Bland J, Haggstrom J, Baduel L, Combes B, Lopez A . Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med. 2010; 24(2):331-41. DOI: 10.1111/j.1939-1676.2009.0467.x. View

Borgarelli M, Savarino P, Crosara S, Santilli R, Chiavegato D, Poggi M . Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med. 2008; 22(1):120-8. DOI: 10.1111/j.1939-1676.2007.0008.x. View

Theilig F, Wu Q . ANP-induced signaling cascade and its implications in renal pathophysiology. Am J Physiol Renal Physiol. 2015; 308(10):F1047-55. PMC: 4436998. DOI: 10.1152/ajprenal.00164.2014. View

Colucci W, Elkayam U, Horton D, Abraham W, Bourge R, Johnson A . Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000; 343(4):246-53. DOI: 10.1056/NEJM200007273430403. View

Yamamoto K, Burnett Jr J, Redfield M . Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol. 1997; 273(5):H2406-14. DOI: 10.1152/ajpheart.1997.273.5.H2406. View

de Madron E, King J, Strehlau G, White R . Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. Can Vet J. 2012; 52(11):1219-25. PMC: 3196016. View

Mizuno T, Mizukoshi T, Uechi M . Long-term outcome in dogs undergoing mitral valve repair with suture annuloplasty and chordae tendinae replacement. J Small Anim Pract. 2012; 54(2):104-7. DOI: 10.1111/j.1748-5827.2012.01305.x. View

Forfia P, Lee M, Tunin R, Mahmud M, Champion H, Kass D . Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol. 2007; 49(10):1079-88. DOI: 10.1016/j.jacc.2006.08.066. View

10.

Vorderwinkler K, Jakob G, Mair J, Diensti F, Pichler M, Puschendorf B . Release of cyclic guanosine monophosphate evaluated as a diagnostic tool in cardiac diseases. Clin Chem. 1991; 37(2):186-90. View

11.

Jensen K, Eiskjaer H, Carstens J, Pedersen E . Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Lond). 1998; 96(1):5-15. View

12.

Uechi M . Mitral valve repair in dogs. J Vet Cardiol. 2012; 14(1):185-92. DOI: 10.1016/j.jvc.2012.01.004. View

13.

Niederkofler E, Kiernan U, ORear J, Menon S, Saghir S, Protter A . Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2009; 1(4):258-64. DOI: 10.1161/CIRCHEARTFAILURE.108.790774. View

14.

Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J . Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009; 23(6):1142-50. DOI: 10.1111/j.1939-1676.2009.0392.x. View

15.

Nakamura M, Arakawa N, Yoshida H, Makita S, Niinuma H, Hiramori K . Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am Heart J. 1998; 135(3):414-20. DOI: 10.1016/s0002-8703(98)70316-3. View

16.

Ovaert P, Elliott J, Bernay F, Guillot E, Bardon T . Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure. J Vet Pharmacol Ther. 2010; 33(2):109-17. DOI: 10.1111/j.1365-2885.2009.01122.x. View

17.

Stasch J, Kazda S, Neuser D . Different effects of ANP and nitroprusside on cyclic GMP extrusion of isolated aorta. Eur J Pharmacol. 1989; 174(2-3):279-82. DOI: 10.1016/0014-2999(89)90321-x. View

18.

McKie P, Schirger J, Benike S, Harstad L, Slusser J, Hodge D . Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. Eur J Heart Fail. 2016; 18(4):433-41. PMC: 4874857. DOI: 10.1002/ejhf.468. View

19.

Takimoto E, Champion H, Li M, Belardi D, Ren S, Rodriguez E . Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005; 11(2):214-22. DOI: 10.1038/nm1175. View

20.

Chen H, Schirger J, Cataliotti A, Burnett Jr J . Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Eur J Heart Fail. 2006; 8(7):681-6. DOI: 10.1016/j.ejheart.2005.12.005. View